Back to News
Market Impact: 0.25
BridgeBio Doses First Participation In ASCENT-ATTR Study
Source: Nasdaq
Healthcare & BiotechCompany FundamentalsCorporate Guidance & Outlook
BridgeBio Pharma (BBIO) dosed the first participant in ASCEND-ATTR, its Phase 3b/4 study assessing the long-term effects of Acoramidis in transthyretin amyloid cardiomyopathy (ATTR-CM). This is an early but tangible trial progress update that can modestly improve sentiment ahead of longer-term efficacy/safety readouts.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
Ticker Sentiment
BBIO0.35
More News
- Nvidia GPUs are everywhere. Here are the ways companies are accessing them
- Bank of America is bullish on these top stocks ahead of earnings
- As companies pour billions into Earth-based AI infrastructure, Google is taking the data center race off-planet
- How U.S. know-how is fracking Australia into a gas boom, from Texas oilmen to Trump’s energy secretary
- The world needs Ukraine’s grain. Its farmers are running out of reasons to plant
- Big Tech is betting $700 billion on AI. Healthcare will decide whether the bet pays off